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Summary
 
A T helper cell type 1–mediated colitis develops in severe combined immunodeficient mice
after transfer of CD45RB
 
high
 
 CD4
 
1
 
 T cells and can be prevented by cotransfer of the
CD45RB
 
low
 
 subset. The immune-suppressive activities of the CD45RB
 
low
 
 T cell population
can be reversed in vivo by administration of an anti-transforming growth factor 
 
b
 
 antibody.
Here we show that interleukin (IL)-10 is an essential mediator of the regulatory functions of
the CD45RB
 
low
 
 population. This population isolated from IL-10–deficient (IL-10
 
2
 
/
 
2
 
) mice
was unable to protect from colitis and when transferred alone to immune-deficient recipients
induced colitis. Treatment with an anti–murine IL-10 receptor monoclonal antibody abrogated
inhibition of colitis mediated by wild-type (WT) CD45RB
 
low
 
 CD4
 
1
 
 cells, suggesting that IL-
10 was necessary for the effector function of the regulatory T cell population. Inhibition of
colitis by WT regulatory T cells was not dependent on IL-10 production by progeny of the
CD45RB
 
high
 
 CD4
 
1
 
 
 
cells, as CD45RB
 
low
 
 CD4
 
1
 
 
 
cells from WT mice were able to inhibit colitis
induced by IL-10
 
2
 
/
 
2
 
 CD45RB
 
high
 
 CD4
 
1
 
 
 
cells. These findings provide the first clear evidence
that IL-10 plays a nonredundant role in the functioning of regulatory T cells that control in-
flammatory responses towards intestinal antigens.
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T
 
he inflammatory bowel diseases encompassing Crohn’s
disease and ulcerative colitis are complex chronic dis-
eases whose etiology and pathogenesis are poorly under-
stood. Recently, several murine models of colitis have been
developed which have highlighted the important role that
abnormalities of the immune system, particularly those
affecting T cells, may play in disease pathogenesis (for re-
views, see references 1 and 2). Studies using T cell–restored
immunodeficient mice have provided evidence that CD4
 
1
 
T cells play a key role in the induction and regulation of
intestinal inflammation, as transfer of CD45RB
 
high
 
 CD4
 
1
 
 
 
T
cells from normal donors into C.B-17 severe combined
immunodeficient (SCID)
 
1
 
 mice led to the development of
a severe inflammatory response in the colon (3, 4). Colitis
was the result of the development of a Th1 response, as po-
larized Th1 cells were present in intestinal lesions and dis-
ease could be prevented by treatment with an anti–IFN-
 
g
 
or anti-TNF mAb (5). More recently, CD45RB
 
high
 
 CD4
 
1
 
T cells isolated from signal transducer and activator of tran-
scription (Stat)-4–deficient mice, which are unresponsive to
IL-12, were shown to be impaired in their ability to trans-
fer colitis to immune-deficient recipients (6, 7).
Cotransfer of the reciprocal CD45RB
 
low 
 
CD4
 
1
 
 T cell
subset together with normally pathogenic CD45RB
 
high
 
cells prevented the development of colitis, indicating that
the CD45RB
 
low
 
 CD4
 
1
 
 
 
subset from normal mice contains a
population of regulatory T cells capable of controlling in-
flammatory responses in the intestine (4). Analysis of the
mechanism of immune suppression revealed a role for
TGF-
 
b
 
 but not IL-4 or IL-10, as anti–TGF-
 
b
 
 mAb but
not anti–IL-4 mAb or anti–IL-10 mAb was able to abro-
gate protection from colitis transferred by CD45RB
 
low
 
CD4
 
1
 
 
 
cells. Indeed, IL-4 appeared to play no demonstrable
role in either the development or effector function of the
regulatory T cell population, as CD45RB
 
low 
 
CD4
 
1
 
 
 
cells
from IL-4–deficient mice were equally as potent as wild-
 
1
 
Abbreviations used in this paper:
 
 LP, lamina propria; RAG, recombination
activating gene; SCID, severe combined immunodeficient; Tr-1, T regu-
latory 1; WT, wild-type. 
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type (WT) cells in inhibiting colitis (8). Despite the finding
that administration of neutralizing anti–IL-10 mAb failed
to inhibit the regulatory activity of CD45RB
 
low
 
 CD4
 
1
 
cells, there is evidence that IL-10 plays an important role in
mucosal immune regulation, as mice with a targeted dis-
ruption of the IL-10 gene developed enterocolitis (9, 10).
In addition, administration of murine rIL-10 prevented
colitis in SCID mice restored with CD45RB
 
high
 
 CD4
 
1
 
 
 
T
cells (5). Furthermore, CD45RB
 
high
 
 CD4
 
1
 
 
 
cells isolated
from transgenic mice that expressed IL-10 under the IL-2
promoter failed to transfer colitis but rather, were able to
inhibit colitis induced by WT CD45RB
 
high 
 
CD4
 
1
 
 
 
T cells
(11). Taken together, these studies provide evidence that
IL-10 is able to regulate pathogenic immune responses in
the intestine; however, whether this suppression involves
the development of regulatory T cells is not known.
In this study, we have analyzed the role of IL-10 in the
development and effector function of regulatory T cells
that control the immune response to intestinal antigens,
and present evidence that IL-10 is essential for the normal
functioning of these cells.
 
Materials and Methods
 
Mice.
 
Specific pathogen-free BALB/c and C.B-17 SCID
mice were obtained from Simonsen Laboratories or Harlan Olac
and maintained in the Animal Care Facility of the DNAX Re-
search Institute or in the Biomedical Services Unit (BMSU) at
the John Radcliffe Hospital. 129/SvEv WT, 129/SvEv recom-
bination-activating gene (RAG)-2–deficient (RAG-2
 
2
 
/
 
2
 
) and
129/SvEv IL-10–deficient (IL-10
 
2
 
/
 
2
 
) mice were bred in isolators
and maintained in microisolator cages with filtered air. Mice
were used at 8–12 wk of age.
 
Antibodies.
 
The following mAbs were used for cell purifica-
tion: 2-43, anti–mouse-CD8 (TIB210; American Type Culture
Collection); M1/70, anti–mouse Mac-1 (TIB128; American
Type Culture Collection); RA3-6B2, anti–mouse B220 (12);
FITC-conjugated anti–mouse CD45RB (clone 16A; PharMin-
gen); and Cy-Chrome–conjugated anti–mouse CD4 (clone
RM4-5; PharMingen). FITC-conjugated anti–mouse IFN-
 
g
 
(clone AN-16; gift of Dr. A. O’Garra, DNAX Research Insti-
tute) and PE-conjugated anti–mouse TNF-
 
a
 
 (clone XT-22;
PharMingen) were used for intracellular staining. The following
mAbs were used in vivo: 1B1.2 (rat IgG1), a blocking mAb reac-
tive with mouse IL-10 receptor (IL-10R) (13), JES5-2A5 (rat
IgG1), an anti–mouse IL-10 mAb (14), and GL113 (rat IgG1), an
isotype control mAb reactive with 
 
b
 
-galactosidase. Unless other-
wise indicated, antibodies were purified from supernatants of hy-
bridomas by ion exchange chromatography and shown to contain
 
,
 
3 EU endotoxin/mg of protein.
 
Cell Purification and Flow Cytofluorography.
 
CD4
 
1
 
 T cell sub-
sets were isolated from spleens as described previously (4). In
brief, single cell suspensions were depleted of B220
 
1
 
, MAC-1
 
1
 
,
and CD8
 
1
 
 cells by negative selection using sheep anti–rat coated
Dynabeads (Dynal Ltd.). The resulting CD4
 
1
 
-enriched cells were
stained with Cy-Chrome–conjugated anti-CD4 and FITC-con-
jugated anti-CD45RB mAb and sorted into the CD45RB
 
high
 
CD4
 
1
 
 and CD45RB
 
low 
 
CD4
 
1
 
 fractions by two-color sorting on
a FACS Vantage™ (Becton Dickinson). All populations were
 
.
 
98% pure on reanalysis.
 
T Cell Reconstitution and Antibody Treatment.
 
RAG-2
 
2
 
/
 
2
 
 mice
or C.B-17 SCID mice were injected intraperitoneally with
sorted CD4
 
1
 
 T cell subpopulations in PBS. mAbs were injected
intraperitoneally in PBS the day after T cell reconstitution and
weekly for the duration of the experiments.
 
Microscopic Examination.
 
Colons were removed from mice
8–12 wk after T cell reconstitution and fixed in buffered 10%
formalin. 6 
 
m
 
m paraffin-embedded sections were cut and stained
with hematoxylin and eosin. Tissues were graded semiquantita-
tively from 0 to 5 in a blinded fashion. A grade of 0 was given
when there were no changes observed. Changes typically associ-
ated with other grades are as follows: grade 1, minimal scattered
mucosal inflammatory cell infiltrates, with or without minimal
epithelial hyperplasia; grade 2, mild scattered to diffuse inflamma-
tory cell infiltrates, sometimes extending into the submucosa and
associated with erosions, with minimal to mild epithelial hyper-
plasia and minimal to mild mucin depletion from goblet cells;
grade 3, mild to moderate inflammatory cell infiltrates that were
sometimes transmural, often associated with ulceration, with
moderate epithelial hyperplasia and mucin depletion; grade 4,
marked inflammatory cell infiltrates that were often transmural
and associated with ulceration, with marked epithelial hyperplasia
and mucin depletion; and grade 5, marked transmural inflamma-
tion with severe ulceration and loss of intestinal glands.
 
Cell Preparation and Cytokine Analysis.
 
Lamina propria (LP)
lymphocytes were purified as described (5). Colons were cut into
0.5–1-cm pieces and incubated in Ca- and Mg-free PBS contain-
ing 10% heat-inactivated FCS (GIBCO BRL) and 5 mM EDTA
to release intraepithelial lymphocytes. The remaining tissue was
further digested with collagenase/dispase (100 U/ml; Sigma
Chemical Co.), and the LP cells were then layered on a Percoll
gradient (Amersham Pharmacia Biotech). The lymphocyte-
enriched population was recovered after centrifugation (600 
 
g
 
, 20
min) at the 40/75% interface. For cytokine detection, freshly iso-
lated LP lymphocytes were cultured for 12 h in RPMI 1640
(PAA Laboratories GmbH) containing 10% FCS, 2 mM 
 
l
 
-glu-
tamine, 0.05 mM 2-ME, and 100 U/ml each of penicillin and
streptomycin in 24-well flat-bottomed plates coated with anti-
CD3
 
e
 
 145-2C11 (10 
 
m
 
g/ml, CRL1975; American Type Culture
Collection). Brefeldin A (10 
 
m
 
g/ml; Sigma Chemical Co.) was
added for the final 2 h of incubation, and surface and cytoplasmic
stainings were performed as described previously (15). Labeled
cells were analyzed on a FACSort™ using CELLQuest™ soft-
ware (Becton Dickinson).
 
Statistical Analysis.
 
Colitis scores were compared using the
Mann-Whitney test, and differences were considered statistically
significant with
 
 P 
 
, 
 
0.05.
 
Results
 
IL-10
 
2
 
/
 
2
 
 Mice Lack Regulatory T Cells Capable of Control-
ling Inflammatory Responses in the Intestine.
 
To determine
whether the CD45RB
 
low
 
 CD4
 
1
 
 
 
population from IL-10
 
2
 
/
 
2
 
mice contained regulatory T cells, this population was
compared with CD45RB
 
low
 
 CD4
 
1
 
 
 
cells from WT mice for
the ability to inhibit colitis induced in RAG-2
 
2
 
/
 
2
 
 mice by
transfer of WT CD45RB
 
high
 
 CD4
 
1
 
 
 
cells. Expression of
CD45RB was similar on CD4
 
1
 
 T cells from 10–12-wk-
old IL-10
 
2
 
/
 
2
 
 and WT mice (data not shown). WT
CD45RB
 
high
 
 CD4
 
1
 
 cells (4 
 
3
 
 10
 
5
 
) were transferred to syn-
geneic RAG-2
 
2
 
/
 
2
 
 mice either alone or in combination
with 2 
 
3
 
 10
 
5
 
 CD45RB
 
low
 
 CD41 cells from WT or IL-102/2997 Asseman et al.
mice. As controls, the CD45RBlow CD41 populations from
IL-102/2 or WT mice were transferred alone and some
mice were not reconstituted. 10–12 wk after T cell recon-
stitution, mice were killed and the development of colonic
inflammation was assessed. As described previously (3, 4),
transfer of CD45RBhigh CD41 cells into RAG-22/2 mice
resulted in the development of severe colitis (Fig. 1 A) in
the majority of mice (63.4%; Table I, top). This colitis was
characterized by an extensive inflammatory cell infiltrate,
marked epithelial cell hyperplasia, and depletion of mucin-
secreting cells. Cotransfer of the CD45RBlow CD41 popu-
lation significantly inhibited (P , 0.005) the development
of colitis, as the majority of mice in this group (83.8%; Ta-
ble I, top) had minimal changes in the intestine (Fig. 1 B).
In contrast, cotransfer of CD45RBlow CD41 cells from IL-
102/2 mice failed to protect mice from colitis, as the ma-
jority of mice in this group (64.2%; Table I, top) developed
intestinal inflammation (Fig. 1 C) identical to that seen in
mice restored with CD45RBhigh CD41 cells alone. Not
only did the CD45RBlow population from IL-102/2 mice
fail to protect from colitis, this population actually induced
disease with similar characteristics (Fig. 1 D) and incidence
(59.0%; Table I, top) to that induced by WT CD45RBhigh
CD41 cells. As described previously (4), immune-deficient
mice either unreconstituted or restored with WT CD45RBlow
CD41 cells exhibited no pathological changes in the intes-
tine (data not shown). These data indicate that production
of IL-10 by CD45RBlow CD41 cells is essential for cells
within this population to mediate their immune-suppressive
function.
Treatment with Anti–IL-10R mAb Abrogated Inhibition of
Colitis Transferred by CD45RBlow CD41Cells. The find-
ing that CD45RBlow CD41  cells from IL-102/2 mice
lacked T cells capable of regulating inflammatory responses
in the intestine appears at odds with previous studies from
this laboratory which showed that treatment with a neu-
tralizing anti–IL-10 mAb failed to abrogate protection from
colitis transferred by CD45RBlow CD41 cells (8). The sim-
plest explanation for these data is that the anti–IL-10 mAb
used (JES5-2A5) in these studies failed to sufficiently neu-
tralize IL-10. Recently, an mAb reactive with the murine
IL-10R has been generated (13) and shown to efficiently
neutralize the effects of IL-10. To test whether treatment
with anti–IL-10R mAb was able to affect the function of
the CD45RBlow population, mice restored with a mixture
of CD45RBhigh and CD45RBlow CD41 cells were treated
weekly with anti–IL-10, anti–IL-10R, or isotype control
mAb. As can be seen in Table I (bottom), treatment with
anti–IL-10R abrogated protection from colitis induced by
the CD45RBlow CD41 population, as all of the mice in
these groups, treated with anti–IL-10R alone or in combi-
nation with anti–IL-10, developed colitis. Antibody treat-
ment alone did not induce immune pathology in the ab-
sence of T cells, as unreconstituted recipients treated with
anti–IL-10R did not develop colitis (data not shown). As
reported previously, anti–IL-10 treatment had no effect on
the immune-suppressive activities of the CD45RBlow pop-
ulation, as mice in this group, like mice treated with iso-
type control mAb, failed to develop colitis.
Colitis induced by the CD45RBhigh CD41 population
was characterized by the accumulation of IFN-g– and
TNF-a–secreting Th1 CD41 T cells in the lesions (Fig. 2
A). A similar expansion of Th1 cells was also present in the
colon of mice that developed colitis after transfer of WT
CD45RBhigh CD41  cells in the presence of WT
CD45RBlow CD41 cells plus anti–IL-10R or after transfer
of IL-102/2 CD45RBlow cells alone. Development of dis-
ease correlated with a significant increase in the total num-
Figure 1. Representative photomicrographs of the descending colon of RAG-22/2 mice after transfer of subpopulations of CD41 T cells from WT or
IL-102/2 mice. (A) Severe colitis in a mouse injected with CD45RBhigh CD41 T cells from WT mice. (B) Normal appearance of the colon in a mouse
restored with WT CD45RBhigh and WT CD45RBlow CD41 T cells, indicating that the WT CD45RBlow population is able to inhibit disease induced by
WT CD45RBhigh CD41 T cells. (C) Severe colitis in a mouse cotransferred with WT CD45RBhigh CD41 T cells and IL-102/2 CD45RBlow CD41 cells,
indicating that the IL-102/2 CD45RBlow subpopulation is unable to protect from the disease. (D) Severe colitis in a mouse receiving only IL-102/2
CD45RBlow cells, indicating that this population is able to induce disease. Hematoxylin and eosin; original magnifications: 350.998 IL-10 and Regulatory T Cells
ber of CD41 T cells expressing IFN-g and TNF-a after
polyclonal stimulation (8–20-fold expansion of CD41
IFN-g1 cells, and 6–34-fold expansion of CD41 TNF-a1
cells; Fig. 2 A) compared with noncolitic mice restored
with a mixture of CD45RBhigh and CD45RBlow cells. The
increase in total Th1 cells characteristic of colitis was due to
the marked increase of CD41 cells in the intestine (Table
II), as analysis of cytokine production at the single cell level
revealed that the few CD41 T cells present in nondiseased
colons were capable of producing similar levels of IFN-g
and TNF-a as those isolated from colitic mice (Fig. 2 B).
The finding that in cotransfers of CD45RBhigh and
CD45RBlow CD41 cells, neutralization of the function
of IL-10 (by treatment with anti–IL-10R or the transfer of
IL-102/2 CD45RBlow cells) led to the development of
colitis with identical immunological and histological fea-
tures to that induced by transfer of pathogenic CD45RBhigh
cells indicates that IL-10 is a key mediator of the regulatory
activity of the CD45RBlow CD41 T cell population.
The Function of Regulatory T Cells Is Not Dependent on the
Differentiation of the Progeny of CD45RBhigh CD41 Cells into
IL-10–secreting Cells. One way regulatory T cells could
mediate their immune-suppressive properties is to induce
the differentiation of naive T cells into cells with a similar
function, rather than into pathogenic cells. This phenome-
non has been termed infectious tolerance (16, 17). Given
that production of IL-10 by CD45RBlow CD41 cells was
essential for their regulatory function and that culture of T
cells in the presence of IL-10 can lead to the generation of
regulatory T cells (18), it is possible that immune suppres-
sion by these cells requires IL-10 production by the nor-
mally pathogenic CD45RBhigh CD41 population.
To test this, CD45RBhigh CD41 cells from IL-102/2
mice were transferred alone or in combination with WT
CD45RBlow CD41 cells to RAG-22/2 mice. As described
previously (19), mice restored with IL-102/2 CD45RBhigh
CD41 cells developed a colitis with similar incidence and
severity (68.0%; Table III) to that transferred by this popu-
lation isolated from WT mice. However, protection from
colitis was equally effective when WT CD45RBlow CD41
cells were cotransferred with IL-102/2 CD45RBhigh CD41
cells, as the majority of mice (81.2%; Table III) had no
colitis or minimal changes in the intestine. These results in-
dicate that inhibition of inflammatory responses in the in-
Table I. The Function of Regulatory T Cells That Control Inflammatory Responses in the Colon Is Dependent on IL-10
Phenotype of CD41 T cells injected
mAb
treatment
No or minimal
colitis (0–1)
Mild
colitis (2)
Severe
colitis (3–5)
RAG-22/2 recipients*
4 3 105 CD45RBhigh – 8/41 (19.5%) 7/41 26/41 (63.4%)
4 3 105 CD45RBhigh
1 2 3 105 WT CD45RBlow – 26/31 (83.8%) 3/31 2/31 (6.4%)‡
4 3 105 CD45RBhigh
1 2 3 105 IL-102/2 CD45RBlow – 6/28 (21.4%) 4/28 18/28 (64.2%)
2 3 105 IL-102/2 CD45RBlow – 5/22 (22.7%) 4/22 13/22 (59.0%)
C.B-17 SCID recipients§
4 3 105 CD45RBhigh – 0/9 3/9 6/9
4 3 105 CD45RBhigh
1 2 3 105 CD45RBlow Isotype control 6/7 1/7 0/7
4 3 105 CD45RBhigh
1 2 3 105 CD45RBlow Anti–IL-10 5/5 0/5 0/5
4 3 105 CD45RBhigh
1 2 3 105 CD45RBlow Anti–IL-10R 0/8 0/8 8/8
4 3 105 CD45RBhigh Anti–IL-10 1
1 2 3 105 CD45RBlow Anti–IL-10R 0/5 2/5 3/5
RAG-22/2 or C.B-17 SCID mice were reconstituted with sorted CD41 T cell subsets and treated for 8 wk with antibodies as indicated (2 mg the
day after T cell reconstitution and 1 mg/wk thereafter for anti–IL-10 mAb and isotype control; 1 mg the day after T cell reconstitution and 0.5 mg/
wk thereafter for anti–IL-10R mAb). 8–12 wk after reconstitution, mice were killed and colonic pathology was graded on a scale of 0–5 as described
in Materials and Methods.
*Data from four to six independent experiments.
‡Statistically different (P , 0.005, Mann-Whitney test) compared with mice restored with 4 3 105 CD45RBhigh.
§Data from two experiments.999 Asseman et al.
testine mediated by CD45RBlow CD41 cells is not depen-
dent on the differentiation of the progeny of CD45RBhigh
CD41 cells into IL-10–secreting cells.
Discussion
Data presented herein provide direct evidence that IL-10
plays an obligate role in the function of regulatory T cells
that control inflammatory responses in the intestine. In
contrast to CD45RBlow CD41 T cells from WT mice,
which inhibit colitis induced in immune-deficient mice
after transfer with CD45RBhigh CD41 T cells, the
CD45RBlow CD41 population from IL-102/2 mice failed
to mediate this function. In addition, they induced severe
colitis when transferred alone to immune-deficient re-
cipients. Previous studies from this laboratory showed
that TGF-b was essential for inhibition of colitis by
CD45RBlow cells (8). These results, together with the find-
Figure 2. IFN-g and TNF-a
production by LP CD41 T cells
from colons. RAG-22/2  or
C.B-17 SCID recipients were
reconstituted with cell subsets as
indicated. 8–12 wk after cell re-
constitution, LP cells were iso-
lated and stimulated for 12 h with
anti-CD3e antibody. Levels of
cytokine expression were deter-
mined by cytofluorography. (A)
Absolute number of CD41 cy-
tokine-positive cells per colon.
Numbers were determined by
multiplying the frequency of cy-
tokine-secreting CD41 T cells
by the total number of CD41
cells. Data represent the mean 6
SEM of two to five animals per
group. (B) Frequency of cyto-
kine-secreting CD41 T cells.
Data are gated on CD41 T cells
and are representative examples
for each group. Horizontal lines
represent staining with isotype
control mAb.1000 IL-10 and Regulatory T Cells
ings reported here, provide the first clear evidence that IL-10
and TGF-b play nonredundant roles in the functioning of
regulatory T cells which control inflammatory responses
towards intestinal antigens, as the neutralization or absence
of one of these cytokines is sufficient to abrogate protec-
tion. Furthermore, IL-10 produced by regulatory T cells
themselves is crucial for the normal functioning of these
cells.
Colitis in the SCID model involves the development of
Th1 cells responding primarily to intestinal flora, as transfer
of CD45RBhigh CD41 T cells to germ-free SCID mice
failed to induce disease (20). The fact that the regulatory
cells express the phenotype of antigen-experienced cells
(CD45RBlow) would suggest that their generation in nor-
mal mice is antigen driven; however, whether these anti-
gens are of bacterial or self origin is not known. Recent
studies of the immune response elicited by Helicobacter he-
paticus infection, a bacterium that colonizes the cecum,
showed that normal mice mounted an IL-10–dependent
response, whereas IL-102/2 mice developed a pathogenic
Th1 response towards the bacterium (21). These studies
support the hypothesis that in immunocompetent hosts,
enteric antigens induce IL-10–secreting T cells that are im-
mune suppressive and prevent inflammatory responses to-
wards intestinal antigens. Mucosal T cell unresponsiveness
to enteric antigens has similarly been shown in humans to
be mediated by antigen-specific CD41 T cells and produc-
tion of IL-10 and TGF-b (22).
Injection of rIL-10 inhibited the development of colitis
in CD45RBhigh CD41 T cell–restored SCID mice (5) and
in IL-102/2 mice treated from weaning (10). However, the
inhibitory effects of IL-10 treatment were only transitory,
as colitis developed after the treatment was stopped,
whereas the transfer of CD45RBlow CD41 T cells provided
long-lasting protection. This may reflect the capacity of
regulatory T cells to provide a constant source of IL-10
upon stimulation by endogenous antigen (bacteria or self).
Alternatively, they may produce or induce other regulatory
molecules, such as TGF-b, which are not induced by ex-
ogenous administration of IL-10.
The finding that CD45RBlow CD41 cells incapable of
synthesizing IL-10 failed to inhibit colitis induced by trans-
fer of CD45RBhigh cells to SCID mice illustrates that the
regulatory T cell population itself is the critical source of
IL-10 in this model, despite the fact that both the
CD45RBhigh  CD41 T cells and host cells in the SCID mice
were capable of making IL-10. It is not clear whether the
lack of regulatory T cells in IL-102/2 mice is a result of ab-
Table II. Development of Disease Correlates with a Significant Increase in the Total Number of Leukocytes and CD41 Cells Recovered
from the LP
Phenotype of CD41 T cells
used for reconstitution
mAb
treatment
Total no. of
LP leukocytes
Total no. of
CD41 cells*
3103 6 SEM 3103 6 SEM
4 3 105 WT CD45RBhigh – 136.0 6 34.9 92.7 6 10.2
2 3 105 IL-102/2 CD45RBlow – 64.4 6 29.7 43.9 6 22.8
4 3 105 WT CD45RBhigh
1 2 3 105 WT CD45RBlow anti–IL-10R 176.3 6 104.5 133.3 6 88.6
4 3 105 WT CD45RBhigh Isotype
1 2 3 105 CD45RBlow control 7.9 6 0.9 5.4 6 0.5
RAG-22/2 or C.B-17 SCID recipients were reconstituted with cell subsets as indicated. 8–12 wk after cell reconstitution, cells from LP were iso-
lated. Data represent the number 6 SEM of two to five animals per group from two independent experiments.
*Total number of CD41 cells were determined by multiplying the number of LP leukocytes by the frequency of CD41 T cells. CD41 T cell fre-
quencies were similar between groups ranging between 60.2 and 81.6%.
Table III. Prevention of Colitis Is Independent of IL-10 Production by CD45RBhigh CD41 T Cells
Phenotype of CD41 T cells injected
No or minimal
colitis (0–1)
Mild
colitis (2) Severe colitis (3–5)
4 3 105 IL-102/2 CD45RBhigh 3/25 (12.0%) 5/25 17/25 (68.0%)
4 3 105 IL-102/2 CD45RBhigh
1 2 3 105 CD45RBlow 26/32 (81.2%) 2/32 4/32 (12.5%)*
RAG-22/2 mice were reconstituted with sorted CD41 T cell subsets. 10–12 wk after reconstitution, mice were killed and colonic pathology was
graded. Data are pooled from four to six independent experiments.
*Statistically different (P , 0.05, Mann-Whitney test).1001 Asseman et al.
normalities in the development or effector function of this
population. However, the finding that treatment with anti–
IL-10R was able to neutralize the immune-suppressive
function of differentiated regulatory cells in cotransfers of
CD45RBhigh and CD45RBlow cells from normal mice sup-
ports the idea that IL-10 is required for the effector func-
tion. The reasons for the striking difference in effectiveness
between the anti–IL-10 mAb JES5-2A5 and the anti–IL-
10R antibody 1B1.2 are not clear, as both are effective
neutralizing antibodies in vitro. However, the relative inef-
fectiveness of JES5-2A5 has been observed in other experi-
mental situations, such as Leishmania-infected mice (Mauze,
S., and R.L. Coffman, unpublished observations).
Precisely how IL-10 mediates its immune-regulatory
function is not known. Inhibition of colitis mediated by
IL-10–secreting CD45RBlow CD41 cells was characterized
by substantial reductions in total number of Th1 cells re-
covered from the intestine. This difference was attributable
to the reduced number of CD41 cells present in the intes-
tine (8–24-fold; Table II), as analysis of cytokine produc-
tion at the single cell level revealed a similar percentage of
CD41 T cells capable of producing IFN-g and TNF-a in
diseased and nondiseased colons. This suggests that the ma-
jor activity of IL-10–secreting regulatory T cells is to in-
hibit the accumulation of pathogenic Th1 cells in the intes-
tine. Whether this is due to reduced expansion, or
migration, of these cells is not known. IL-10 has been
shown to mediate a range of antiinflammatory activities,
including the inhibition of antigen-induced proliferation
and cytokine secretion by T cells. Inhibition is thought to
be mediated mainly by effects on APCs, particularly down-
regulation of molecules involved in T cell costimulation
(23). It seems likely that IL-10–secreting regulatory T cells
act to inhibit Th1 cell activation, and that IL-10 produced
locally in the intestine acts on macrophages to prevent their
activation and elaboration of proinflammatory molecules
and chemokines, thus inhibiting T cell recruitment into the
intestine. Consistent with this, mice in which macrophages
and neutrophils are unable to respond to IL-10 as a result of
a cell type–specific deletion of Stat-3 developed enterocoli-
tis (24), suggesting that IL-10–mediated macrophage and
neutrophil deactivation contributes to the immune-sup-
pressive properties of IL-10 in the intestine.
Recently, regulatory cells with activities similar to those
within the CD45RBlow CD41 population were cloned in
vitro by culturing with IL-10 (18). These cells, termed T
regulatory 1 (Tr-1) cells, are characterized by their ability
to produce IL-10 but not IL-4 and to inhibit T cell activa-
tion in vitro and in vivo. Although immune suppression in
vitro was shown to be dependent on IL-10 and TGF-b,
the mechanism of action of Tr-1 cells in vivo has not been
established. It is likely that regulatory T cells contained
within the CD45RBlow CD41 subset represent the in vivo
counterpart of in vitro–derived Tr-1 cells. This is based on
the fact that the function of the former population is de-
pendent on IL-10 but not IL-4 synthesis, a defining feature
of Tr-1 cells in vitro. In addition, a subset of CD45RBlow
CD41 T cells, identified by expression of CD38, was
shown to be immune suppressive in vitro and to produce
IL-10 but not IL-4 after stimulation with anti-CD3 and
IL-2 (25). However, further comparison between the in
vivo–derived regulatory cells described here and in vitro–
derived Tr-1 cells awaits identification of cell surface mark-
ers specific for Tr-1 cells and elucidation of their mecha-
nism of action in vivo.
The finding that IL-10 leads to the differentiation of Tr-1
cells in vitro raised the possibility that part of the mecha-
nism by which IL-10–secreting regulatory T cells con-
tained within the CD45RBlow CD41 population inhibit
colitis is to induce the differentiation of the progeny of
CD45RBhigh CD41 cells into IL-10–secreting cells. In
some systems, regulatory T cells have been shown to in-
duce the differentiation of naive cells into cells with similar
regulatory function, a phenomenon termed infectious tol-
erance (16, 17). However, differentiation of Tr-1 cells
among the progeny of the CD45RBhigh population did not
appear to be a crucial part of the immune-suppressive ac-
tivities of the CD45RBlow population, as these cells were
able to inhibit colitis induced by IL-102/2 CD45RBhigh
CD41 cells which could not differentiate into IL-10–secret-
ing cells. However, this result does not rule out the possi-
bility that IL-10 secretion by the CD45RBlow population
leads to the differentiation of the progeny of CD45RBhigh
cells into regulatory T cells secreting other cytokines, for
example TGF-b, and experiments are currently underway
to test this hypothesis.
In summary, these studies identify IL-10 as an essential
mediator of the function of regulatory T cells contained
within the CD45RBlow CD41 T cell population. Previous
studies identified TGF-b as a critical component of the im-
mune-regulatory function of these cells, and the finding
that IL-10 has an identical effect is the first demonstration
that both of these immune-suppressive cytokines play man-
datory roles. How the functions of these two cytokines are
linked is not known. The finding that IL-102/2 mice have
immune pathology restricted to the intestine (9) whereas
TGF-b12/2 develop multiple organ disease (26) suggests
that IL-10 is not required for the production of TGF-b1.
However, TGF-b has been shown to induce IL-10 secre-
tion by APCs (27), making it a possibility that TGF-b alters
antigen presentation in favor of the generation of IL-10–
secreting regulatory T cells. Alternatively, IL-10 and TGF-b
may act entirely separately, and further experiments are re-
quired to distinguish between these possibilities.
There is now good evidence that regulatory T cells can
be induced after oral exposure to antigen and that their
function is dependent on TGF-b (28, 29). In addition, reg-
ulatory T cells that inhibit the development of autoim-
mune disease have been shown to exist naturally in mice
and rats (for a review, see reference 30). However, infor-
mation regarding the role of IL-10 and TGF-b in the func-
tion of these cells is incomplete, as in most cases only one
or the other has been examined. Thus, TGF-b–dependent
mechanisms were shown to be involved in the regulation
of autoimmune nephritis (31) and thyroiditis (32), whereas
inhibition of diabetes by NK1.1 T cells was dependent on1002 IL-10 and Regulatory T Cells
IL-4 and IL-10 (33). It remains to be established whether
regulatory T cells that control inflammatory responses in
the gut are the same as those shown to regulate organ-spe-
cific autoimmune disease. However, more information on
the relative roles of IL-10 and TGF-b in the function of these
different populations of cells will facilitate their compari-
son. Differentiation of IL-10–secreting TGF-b–dependent
regulatory T cells is one of the host’s natural mechanisms
for avoiding immune pathology. Further understanding of
the antigen specificity, development, and mechanism of ac-
tion of these cells is crucial for the design of effective im-
mune interventions that seek to capitalize on this potent
immune-regulatory mechanism.
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